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Azlocillin was more active in vitro than ticarcillin or carbenicillin against 561
aminoglycoside-resistant strains of Pseudomonas aeruginosa collected from 74
hospitals distributed over a wide geographic area in the eastern United States.
Azlocillin was compared with various other antimicrobial agents in discriminative
animal models of Ps. aeruginosa pyelonephritis, osteomyelitis, endocarditis, and
meningitis in a variety of mammalian species.
Cefsulodin was more effective than azlocillin in reducing Ps. aeruginosa kidney
concentrations in rat pyelonephritis induced by intrarenal inoculation. The
mean±s.D. log l 0 cfu/g kidney after three days of therapy were as follows:
controls = 5-4±1-5, azlocillin=4-4±1-8, cefsulodin = 2-6±0-9 (/»-0-01) but the
MBC for the test strain was eight-fold higher for azlocillin (8 vs. 1 mg/1) and
effective concentrations were maintained longer in rat serum for cefsulodin as
against azlocillin. In addition, ticarcillin reduced kidney bacterial concentrations
faster than azlocillin in a mouse pyelonephritis model induced by intravenous Ps.
aeruginosa inoculation with subsequent iron loading.
Azlocillin was less effective than tobramycin in experimental chronic Ps.
aeruginosa osteomyelitis induced in rabbits by direct injection into the tibia. An
azlocillin-tobramycin regimen was not more effective than tobramycin alone. After
28 days of therapy, the percentages of positive bone cultures after death were as
follows: no antibiotic (controls) = 92%, azlocillin = 95%, tobramycin = 76%,
azlocillin plus tobramycin = 60%.
Both ticarcillin and azlocillin were less active than tobramycin in experimental Ps.
aeruginosa endocarditis induced in rabbits by intravenous inoculation of 108 cfu
following 1 h of catheter induced aortic valve trauma. The best results were noted
with an azlocillin-tobramycin regimen. The mean±s.D. log,0 cfu Ps. aeruginosa/g
vegetation after five days of therapy were as follows: no antibiotic controls
= 81 ± 1 1 , tobramycin=4-5 ±0-8, ticarcillin = 6-9 ±0-8, azlocillin = 5-7 ± 1-5,
ticarcillin phis tobramycin=4-9+1-0, azlocillin plus tobramycin = 3-3 ± 1-6. Sterile
vegetations were rarely attained with any regimen.
The mean percentage penetration into purulent cerebrospinal fluid (CSF) in
experimental Ps. aeruginosa meningitis for azlocillin was 13-3%, comparable to
many other /J-lactam antibiotics. Azlocillin was the single most active (P-0-0\)
agent evaluated after 8 h intravenous infusions in this model. An azlocillin-amikacin
regimen was more rapidly bactericidal ( P < 0 0 1 ) than either agent alone in vivo.
None of the agents evaluated alone or in combination, however, produced a sterile
CSF after 8 h of therapy in any animal.
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Introduction
Azlocillin is a new ureidopenicillin with a wide in-vitro spectrum of activity,
particularly against the Enterobacteriaceae and Pseudomonas aeruginosa (Calderwood
et al.. 1982; Coppens & Klastersky, 1979; Eliopoulos & Moellering, 1982; Ellis et al..
1979; Fass, 1982; Fu & Neu, 1978; Greenwood & Eley, 1982; Hoogkamp-Korstanje,
Pot & Westerdaal, 1981; Neu & Fu, 1978; Slack, 1981; Tselentis et al.. 1981; White,
Comber & Sutherland, 1980; White et al.. 1979; Wise, Andrews & Bedford, 1978a).
The in-vitro activity against Ps. aeruginosa surpasses carbenicillin, ticarcillin, and
mezlocillin, and is comparable to piperacillin and cefsulodin (King, Shannon &
Phillips, 1980; Kuck, Testas & Forbes, 1981; Perea et al.. 1980; Wise et al.. 1978*).
Because of these excellent in-vitro properties, all of these agents have been investigated
in experimental animal models of infection. Unlike mezlocillin (Scheld, Brodeur &
Keeley, 1981), azlocillin has been evaluated in a wide variety of discriminative
experimental models. Most of the data is either unpublished or available only in
abstract form.
Three main types of experimental models are used in experimental chemotherapy:
basic screening (i.e. the mouse protection test), ex vivo, or discriminative. The first two
types suffer from multiple inherent problems but discriminative models generally
simulate known pathogenic mechanisms more closely (Zak, 1980; Scheld & Sande,
1982). Only discriminative models are considered in this review.
The objective of this study was to describe the cumulative experience with azlocillin
in discriminative animal models of infection. This analysis considers published results
in experimental osteomyelitis and pyelonephritis (Norden & Shaffer, 1982; Beale,
Comber & Sutherland, 1982) as well as our own unpublished, but reported, data in
experimental pyelonephritis, endocarditis, and meningitis.
Methods
General analysis. A thorough literature search disclosed that the in-vivo activity of
azlocillin was evaluated and reported in only two previous studies of experimental
osteomyelitis and pyelonephritis (Norden & Shaffer, 1982; Beale et al., 1982). These
experiments are summarized below. Other studies were identified through Drs George
Arcieri and Douglas Webb (Miles Pharmaceuticals, West Haven, Connecticut, U.S.A.)
and personal communication with other investigators active in the field of
experimental antibacterial chemotherapy. Data were kindly provided by Dr Otokar
Zak of Ciba-Geigy Ltd. (Basle, Switzerland) on experimental pyelonephritis; these
experiments are also summarized below.
In-vitro studies. Minimal inhibitory concentrations (MICs) and minimal bactericidal
concentrations (MBCs) were determined for azlocillin and the other agents studied in
the experimental animal models of infection by standard broth microdilution
techniques (Cooke Engineering Co., Alexandria, Virginia, U.S.A.). After overnight
(18 h) incubation, the organisms were centrifuged (3000gx 15 min), washed twice in
physiologic saline, and serially diluted to ensure an inoculum of 5 x 105 cfu/ml
Mueller-Hinton broth (Difco). The MIC was read as the lowest concentration of
antibiotic that inhibited visible turbidity after 18 h incubation at 37°; the MBC was
taken as the lowest concentration of drug that completely sterilized the wells as verified
by subculture onto drug free media and further incubation at 37° for 24 h.
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In addition to determination of broth dilution MICs and MBCs for the Ps.
aeruginosa strains used in the in-vivo experiments, Mueller-Hinton agar dilution MICs
(inoculum = 5 x 105 cfu) were determined for azlocillin, ticarcillin and carbenicillin
against 561 strains of Ps. aeruginosa isolated from multiple sites collected from 74
hospitals spread over a wide geographic area as part of an ongoing surveillance system
for antibiotic resistance among aerobic Gram-negative bacillary nosocomial isolates
(Wenzel el al., 1979). Concentrations of 2-32 mg/1 of each antibiotic were incorporated
into the agar; the strains were deposited on the surface with a Steer's replicator (Steers,
Foltz & Graves, 1959). The results were read after 24 h of incubation at 37°.
Preparation of bacteria. The Ps. aeruginosa strains used in the in-vivo experiments
(see below) were all clinical isolates and the inocula were prepared by similar methods.
The organisms were grown for 16 to 18 h in trypticase soy broth (TSB; Difco) at 37°,
centrifuged at 3000 g x 15 min, and washed twice in non-bacteriostatic physiologic
saline. The pellet was resuspended in 20ml PBS and serial diluted ten-fold in PBS
prior to quantitative determinations in trypticase soy agar pour plates. The inoculum
varied with the experimental model of infection under consideration from a; 106
to>108 (see below).
Experimental pyelonephritis. Azlocillin was compared with cefsulodin in
experimental pyelonephritis induced in male 180-200 g Wistar rats by the intrarenal
inoculation of 106 cfu Ps. aeruginosa (ATCC 12055). Both agents were administered at
a dosage of 1 mg/kg subcutaneously twice daily for three days, beginning 6 h after
inoculation. Quantitative renal cultures were performed 36 h after the last dose by
standard homogenization, serial dilution, and pour plate techniques on CLED agar
(Oxoid). The results were expressed as cfu/g kidney and the number of sterile
kidneys/total number animals treated in each group.
Another model (Beale et al., 1982) compared the ureidopenicillins with ticarcillin in
experimental Ps. aeruginosa pyelonephritis induced in mice by the intravenous
administration of 2 x 106 cfu followed by the intramuscular injection of 30 mg/kg of
iron 18, 42, and 66 h after injection. Therapy was instituted at either 19 or 43 hours
after infection, at varying dosages, and continued four times daily for three days.
Three strains of Ps. aeruginosa were used in these experiments. The results were
assessed as the percentage of kidneys with macroscopic abscesses and viable count
deteminations of kidney homogenates by standard techniques counted seven days after
infection.
Experimental osteomyelitis. Chronic Ps. aeruginosa osteomyelitis was induced in
rabbits by the intramedullary injection into the tibia of 2 x 107 cfu plus sodium
morrhuate (Norden & Shaffer, 1982). The model was developed from methods used
previously to induce chronic staphylococcal osteomyelitis (Norden, 1970), and, by
radiographic and pathological criteria, closely simulates the human disease (Norden,
Myerowitz & Keleti, 1980). Treatment was begun 14 days after inoculation and
continued for 14 or 28 days. The dosages (in mg/kg, all given subcutaneously) of the
antibiotics tested were as follows: tobramycin—10, twice daily; azlocillin—400, four
times daily. Each agent was administered alone, and in combination, and compared to
untreated controls. The animals were killed 70 days after inoculation and bone
cultures obtained by flushing the marrow cavity (Norden, 1970). The results were
expressed as the percentage of animals with positive bone cultures in each group.
Experimental endocarditis. Endocarditis was induced in 2-3 kg New Zealand white
rabbits by modifications of methods described previously (Archer & Fekety, 1976,
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1977; Durack, Beeson & Petersdorf, 1973; Freedman & Valone, 1979; Scheld et al,
1981, 1982). A polyethylene catheter (Intramedic, Clay-Adams, New Jersey, U.S.A.;
PE-90) was introduced through the right carotid artery and threaded across the aortic
valve into the ventricle. The catheter was left in place for 1 h; this period of trauma
uniformly results in the deposition of fibrin and platelets with the production of non-
bacterial thrombotic endocarditis (NBTE) on the damaged aortic valvular
endothelium (Sande & Irvin, 1974; Scheld, Valone & Sande, 1978). After this interval,
6xl08cfu washed Ps. aeruginosa in 10 ml saline were injected intravenously. The
strain was isolated originally from a fatal case of endocarditis at the University of
Virginia hospital in 1976 and was not serum sensitive. Following inoculation, the
catheter was removed and the wound closed. Quantitative blood cultures (10 ml) were
obtained 24h later and treatment begun. The dosages (mg/kg) were as follows:
tobramycin—5; azlocillin and ticarcillin—200. All drugs were given intramuscularly
every 8 h for five days. Blood was drawn frequently (i.e. 0-5, 1, 1-5, 2, 3, 4, 6, and 8 h)
for determination of serum antibiotic levels on the second day of therapy. In addition,
blood was obtained for determination of 'peak' and 'trough' serum bactericidal
activity against the infecting strain. Only febrile animals with positive blood cultures
(mean = log,0 2-6cfu/ml) were considered infected (>95% of those catheterized) and
included in the analysis.
The animals were killed 8 h after the last dose of antibiotics). The aortic valve
with vegetations was removed aseptically, weighed, homogenized, and titered by serial
ten-fold dilutions onto trypticase soy agar pour plates. The results were expressed as
the mean±log10 Ps. aeruginosa cfu/g of vegetation. At least ten rabbits were included
in each treatment group.
Experimental meningitis. Meningitis was induced in 2-3 kg New Zealand white
rabbits by modifications of methods described previously (Dacey & Sande, 1974;
Scheld et al., \919a,b. 1982). A dental acrylic helmet was attached to the animal's skull
to facilitate rigid immobilization within a stereotaxic frame. After a two or three day
interval, and light pentobarbital (30 mg/kg) anaesthesia, the rabbits were positioned in
the stereotaxic frame. The cisterna magna was entered percutaneously with a 25
gauge x 3-5 in Quincke spinal needle mounted in a geared electrode introducer. After
withdrawal of 0-35 clear CSF, the inoculum (107 cfu Ps. aeruginosa in 015 ml saline)
was injected slowly and the animals returned to their cages. All rabbits developed
meningitis as manifested by fever (>40°C), neurologic signs (e.g. seizures,
opisthotonus, lethargy), a CSF pleocytosis (mean log10 3-6wbc/mm3 CSF; ^95%
polymorphonuclear leukocytes), and CSF Pseudomonas concentrations that ranged
from 104 to > 108 cfu/ml (mean log,0 602 cfu/ml CSF). The meningitis was uniformly
fatal in untreated animals with death occurring ^42 h after inoculation.
After reinduction of anaesthesia, placement of polyethylene catheters (Intramedic
PE-90, Clay-Adams, Parsippany, N.J., U.S.A.) in the femoral artery and vein, and
repositioning in the stereotaxic frame with intracisternal needles in place, treatment
was begun 18 h after inoculation. All antibiotics were given via continuous intravenous
infusion over 8 h by a syringe infusion pump (Sage model 352) attached to the femoral
venous catheter, at the following dosages (in mg/kg/h): all /?-lactams—80; all
aminoglycosides—2-5. A loading dose, representing 20% of the total dose delivered
over the 8 h interval, was given by short (2-3 min) intravenous bolus infusion
immediately prior to the start of therapy. Serum (3 ml) and CSF (0-25 ml) samples
were removed from the femoral arterial catheter and cisterna magna, respectively,
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immediately before and after 4 and 8 h of treatment for quantitative bacterial and
antibiotic concentrations. CSF bacterial titers were quantitated by standard ten-fold
serial dilution techniques, as well as direct plating (01 ml) on trypticase soy agar pour
plates. The remainder of the CSF, along with the serum samples, were frozen at —70°
until antibiotic assays were performed (<; 1 week). This period of storage did not affect
the assay results.
Antibiotic assays. Antibiotic levels were determined by agar well diffusion methods.
Bacillus subtilis spore suspension (0-9 ml) was added to 1000 ml antibiotic medium no.
1 (Baltimore Biologic Laboratories, U.S.A.) for all penicillin assays, including
azlocillin. Aminoglycoside concentrations were assayed with a multidrug resistant
strain of Staphylococcus epidermidis (ATCC 27626) as described previously (Alcid &
Seligman, 1973). Cefsulodin concentrations were determined with a 2-5% v/v
suspension of Sarcina lutea (ATCC 9341) in antibiotic medium no. 1, previously
adjusted to yield 21% transmission at 580 nm on a Gilford spectrophotometer. All
specimens and standards were tested in triplicate. Serum standards were made fresh on
the day of assay with appropriate diluent (e.g. rabbit or rat serum), while CSF
standards were prepared in 0-9% NaCl after equivalent zone sizes were noted after
dilution in 0-9% NaCl, infected or uninfected rabbit CSF.
Analysis of data. When the end-point for analysis of therapy was cfu/unit tissue (e.g.
kidney, vegetation, CSF etc.), Student's Mest on unpaired data was used to detect any
differences between regimens. When the end-point was percentage sterility (or per cent
with positive cultures), %2 analysis with Yate's correction was used. The per cent
penetration of antibiotics into the CSF was defined by the formula: CSF
concentration/serum concentration x 100.
Results
In-vitro studies. The MBCs obtained with each of the Ps. aeruginosa strains used in
the in-vivo models of experimental infection are shown below in the appropriate tables.
The MICs obtained for azlocillin, ticarcillin, and carbenicillin against 561 isolates of
Ps. aeruginosa collected from nosocomial infections in 74 hospitals from a four state
geographic area in the eastern United States are displayed in Figure 1. Azlocillin was
the most active anti-pseudomonal /Mactam agent tested. For example, at a
concentration of 8 mg/1, the percentage of strains inhibited by each agent was as
follows: azlocillin—651%, ticarcillin—14-4%, carbenicillin—3-2%. The median MICs
were as follows (in mg/1): azlocillin—8, ticarcillin—16, and carbenicillin—^64.
Azlocillin was equally active against carbenicillin-sensitive or resistant
(MIC £ 128 mg/1) Ps. aeruginosa isolates in this study (data not shown).
Experimental pyelonephritis. Azlocillin was less active than cefsulodin in the rat
pyelonephritis model when analysed in terms of log10cfu Ps. aeruginosa/g kidney or
the total number of positive kidney cultures obtained (Table I). When given at
identical dosages (1 mg/kg bidx3 days) kidney bacterial concentrations were higher
(P- 001) after azlocillin therapy when compared to cefsulodin. Even when the
azlocillin dosage was increased to 5 or 10 mg/kg per injection, the mean recovery of Ps.
aeruginosa still exceeded 4 logs per kidney (O. Zak, pers. comm.). However, the MBC
for the test strain was eight-fold higher for azlocillin than cefsulodin. In addition, as
shown in Figure 2, therapeutic concentrations of cefsulodin are maintained in rat
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Fljure 1. Cumulative percentage of Ps. aeruginosa strains (n=561) inhibited vs. antibiotic concentration
(mg/l) for: azlocillin ( • # ) , ticarcillin ( • # ) , and carbeniciUin (O CO-
serum for much longer periods than was noted after equivalent (or higher) dosages of
azlocillin.
Azlocillin was less effective than ticarciUin in the mouse model of experimental Ps.
aeruginosa pyelonephritis as well (Table II). The results are expressed as the percentage
of animals with macroscopically visible abscesses on the cortical surface after death
which correlates well with kidney tissue homogenate viable counts of ^ 107 cfu/g.
When the antibiotics were begun 19 h after infection, azlocillin at 125 mg/kg did not
prevent abscess formation but ticarcillin produced 60% negative cultures at the same
dosage. Similar differences were noted after a higher dosage of 500 mg/kg against this
Ps. aeruginosa strain NCTC 10662 (Table II; Beale et al., 1982). When antibiotic
therapy was delayed until 43 h post-infection, mean kidney bacterial
concentrations had increased to = 10s cfu/g from the value of ~ 102 cfu/g at 19 h, the
efficacy of therapy was attenuated, but ticarcillin still rendered more kidneys free of
infection than did azlocillin (Table II). When these experiments were extended to two
other strains of Ps. aeruginosa in the same animal model, ticarcillin proved more
effective than azlocillin and piperacillin at identical dosages of 250 mg/kg; mezlocillin
Table I. Results of therapy in experimental Ps. aeruginosa pyelonephritis*
No. positive kidney cultures/
tsttai «/•* troa tostDrug MBC (mg/l)
Mean±s.D.
log
 10 cfu/g kidney total no. treated
None
Azlocillin
Cefsulodin
5-4± 15
4-4 ±1-8
2-6±O9
12/12
8/10
1/12
•After Zak, O, Tosch, W. & ICradolfer F. (1980). Therapeutic efficacy of cefsulodin in severe experimental
Ps. aeruginosa infections. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstract no. 460; and Zak, O., personal communication.
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Figure 2. Pharmacokinetics of azlocillin (50mg/kg; © ©) and cefsulodin (30mg/kg; © ©)
after subcutaneous injection in adult rats. Mean plasma concentration (mg/1) vs. time after injection (h).
was the least active agent in this setting (data not shown; Beale et al, 1982).
'Experimental osteomyelitis. The results of therapy in the model of chronic Ps.
aeruginosa osteomyelitis are shown in Table III. The severity of the disease, as judged
by radiographic criteria, was similar in each group and approximately 30% of the
animals had developed sequestra before death, 70 days after inoculation. The
data are presented for the 28 day treatment regimens only. Azlocillin alone was no
more effective than no treatment (>90% positive bone cultures); tobramycin alone
was more effective (Table III). The azlociUin-tobramycin combination regimen was
more effective than either no treatment or azlocillin alone (P-- 005 by /2 analysis)
but was not significantly more effective than tobramycin alone (Table III).
Table II. Results of therapy in experimental Ps. aeruginosa pyelonephritis*
% Mice with visible kidney abscesses when
therapy was begun at:
43 h
90
80
70
70
20
•After Beale et al., (1982).
Drug
None
Azlocillin
Ticarcillin
Dosage (mg/kg)
125
500
125
500
191
90
100
40
40
0
Table ID. Results of therapy in experimental Ps. aeruginosa osteomyelitis*
% with positive bone cultures
Drug MIC (mg/1) Mean 'peak' [bone] mg/g after 28 days treatment
92
95
76
60
None
Azlocillin
Tobramycin
Azlocillin plus
tobramycin
—
12 5
0-2
—
290
2-6
•After Norden, C. W. & Shaffer, M.A. (1982).
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- • ) , azlocillin (200mg/kg;
— • ) , andFigure 3. Pharmacokinetics of tobramycin (5 mg/kg; • •
ticarcillin (200 mg/kg; O O) after intramuscular injection in adult rabbits with experimental Ps.
aeruginosa endocarditis. Mean ± s.D. serum concentration (mg/1) vs. time after injection (h).
Experimental endocarditis. The serum concentrations of tobramycin, ticarcillin, and
azlocillin in rabbits with experimental endocarditis closely approximated those found
in man receiving standard parenteral regimens (Figure 3). The mean 'peak' serum
levels occurred 30 min after im injection and were 11-2, 2850, and 228-3 mg/1 for
tobramycin, ticarcillin, and azlocillin, respectively. Tobramycin was almost
undetectable in serum samples drawn 8 h after a dose, whereas azlocillin persisted
longer in the serum than did ticarcillin after equivalent dosages (Figure 3). The median
'peak' serum bactericidal litres were as follows: tobramycin alone—1 : 2; ticarcillin
alone—1 : 16; azlocillin alone—1 : 16; azlocillin plus tobramycin—1 : 32. All trough
serum bactericidal titres were < 1 : 2 except for the azlocillin-tobramycin combination
regimen where the median (and highest) values were 1 :4.
The results of therapy of experimental endocarditis in this model are shown in Table
IV. The mean bacterial concentration in untreated control vegetations was log)0
81 cfu/g, in good agreement with other models of experimental Ps. aeruginosa
endocarditis (Archer & Fekety, 1976, 1977). Tobramycin alone was more effective than
either /Mactam agent alone in reducing Ps. aeruginosa vegetation concentrations after
five days of therapy (mean log,0 cfu/g 4-5 vs. 6-9, P- 001; 4-5 vs. 5-7, P = NS). The
tobramycin-ticarcillin regimen was not more effective than tobramycin alone.
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Table IV. Results of therapy in experimental Ps. aeruginosa endocarditis
Drug(s)
None
Tobramycin
Ticarcillin
Azlocillin
Tobramycin +
ticarcillin
Tobramycin +
azlocillin
MBC (mg/1)
4
32
16
Mean + S.D.
log,0cfu/g vegetation
81 + 11
4-5 + 0-8
6-9 + 0-8
5-7+1-5
4-9 ± 1 0
3 3± 16
No. sterile veg/
total number treated
0/10
1/10
0/13
1/12
2/14
4/14
Azlocillin plus tobramycin produced the best results with a mean recovery of 3-3 logs
at death (P<005 vs. tobramycin alone; P<00l vs. azlocillin alone). Sterile
vegetations were achieved rarely, however. For example, only 4 of 14 rabbits in the
azlocillin-tobramycin combination group had sterile vegetations after five days of
therapy vs. 1 of 10 in the tobramycin group (P = NS).
Experimental meningitis. The mean ± S.D. serum and CSF concentrations obtained
and the percentage penetration into infected CSF for the various antibiotics employed in
these experiments are shown in Table V. For each antibiotic, serum concentrations
reached a 'steady-state' level within 1 h of intravenous infusion initiation, and closely
approximated those found in man receiving standard parenteral regimens. The CSF
concentrations reflect these differences in serum concentrations as well as the abihty of
the agent to cross inflamed meninges and maintain steady-state concentrations within
purulent CSF. The mean percentage penetration into the infected CSF was reproducible
and consistent for each agent but varied over a wide range. This value was > 25% for
all aminoglycosides, and was similar for structurally-related compounds (e.g. azlocillin
and mezlocillin). These values are in close agreement with those reported in other
models of experimental meningitis in rabbits (Strausbaugh, Mandaleris & Sande, 1977;
Strausbaugh & Sande, 1978; Scheld et al., \919a,b).
The mean CSF concentration exceeded the MBC for the test strain for the
aminoglycosides, azlocillin, piperacillin, and cefsulodin. Despite this relationship, the
Table V. Mean serum and cerebrospinal fluid (CSF) concentrations and percentage penetration
into the CSF for various antibiotics in experimental Ps. aeruginosa meningitis
Drug
Gentamicin
Tobramycin
Amikacin
Carbenicillin
Ticarcillin
Mezlocillin
Azlocillin
Piperacillin
Cefsulodin
No. animals
21
19
26
10
17
27
31
18
16
Mean ± S.D.
(Serum)
131+ 3-6
15-6+ 41
23-2+ 5-3
73-2 + 31-2
82-9 + 38-8
179-9+18-9
248-2 + 22-4
148 6±18 4
209-4 ±15-6
Mean ± S.D.
(CSF)
4-0 ± 1-5
3-6+ 1-5
8-6± 1-8
6-9± 30
7-8± 31
23-7+ 5-5
29-4+11-7
23-3 ± 4-2
29-9+12-8
Mean%
penetration*
28-7
24-4
35-3
9-4
9-5
13-5
13-3
15-7
150
• = (CSF)/(Senim)xlOO.
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Figure 4. Rate of bacterial killing in experimental Ps. acruginosa meningitis by: no antibiotic (I
• ), gentamicin ( • • ) , tobramycin (O O), amikacin (O O), azlociUin (A-
azlocillin plus gentamicin (
(A
A). azlociUin plus amikacin
A)- Dosages employed (in mg/kg/h): all aminoglycosides = 2-5; azlociUin = 80.
-A), azlociUin plus tobramycin (A-
rate of bactericidal activity in vivo was poor in this model of experimental Ps.
aeruginosa meningitis (Table VI; Figure 4). Despite the mean CSF drug concentrations
of up to four times the MBC of the infecting strain, none of the aminoglycosides
reduced CSF Ps. aeruginosa concentrations when compared to untreated controls
(Table VI). Azlocillin was more effective, with a mean reduction of 21 logs after 8 h of
therapy (/><- 001 vs. aminoglycosides or controls). Azlocillin was the most active p-
lactam agent tested, only ticarcillin and cefsulodin produced declines > 1 log in CSF
Ps. aeruginosa concentrations after 8 h. Some azlocillin-aminoglycoside regimens were
more rapidly bactericidal in vivo than azlociUin alone, but these differences were
statistically significant for the azlocillin-amikacin regimen only (P*- 002 vs. azlociUin
Table VI. Results of therapy in experimental Ps. aeruginosa meningitis
Mean±s.D. A log)o cfu/ml CSF
Drug(s) MBC (mg/1) Mean [CSF] mg/1 after 8 h of therapy
Gentamicin
Tobramycin
Amikacin
Azlocillin
Azlocillin +
gentamicin
Azlocillin+
tobramycin
Azlocillin +
amikacin
None (controls)
1
1
2
8
4 0
3-6
8-6
29-4
+ 06±0-8
+ 01 ±0-8
+ 0-3±0-7
— 2-1 ± 1-2
- 1 - 8 + 1 1
-2-4±l-4
-3-6 ±0-8
+ 0-8 ±0-4
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alone) (Table VI, Figure 4). It should be noted, however, that treatment with a
cefsulodin-amikacin regimen produced equivalent results; a mean reduction in CSF
bacterial titre of — 3-5 logs in 8 h (n = 6; data not shown). None of the regimens examined
produced a sterile CSF after the treatment interval in a single animal.
Discussion
This report summarizes the experience with azlocillin in discriminative animal models
of infection. Despite extensive clinical trials conducted in Europe and the United
States, information regarding the in-vivo efficacy of azlocillin in experimental infections
is scant. This compound has now been evaluated in a wide range of experimental
infections recently (all induced by Ps. aeruginosa), including pyelonephritis,
osteomyelitis, endocarditis and meningitis, and these models are considered in this
study. Since azlocillin will be used for serious infections caused by Ps. aeruginosa,
including those occurring in neutropenic or other types of immuno-suppressed
patients, it is surprising that none of the newer /Mactam agents has been evaluated in
any of the excellent models for bacteraemia in neutropenic animals (Winston et al.,
1979; Scheld & Sande, 1982). Studies with azlocillin and other new 0-lactam agents are
currently under investigation in neutropenic animals with a wide variety of
experimental infections (Douglas Webb, pers. comm.).
Azlocillin was more active than ticarcillin or carbenicillin against the Ps. aeruginosa
isolates tested in vitro in this study (Figure 1). This activity confirms previous reports
(Coppens & KJastersky, 1979; Fu & Neu, 1979) and is particularly noteworthy since a
large number (n = 561) of strains from 74 hospitals spread over a wide geographic area
were included in the study. Previous evaluations have tested only small numbers of
strains from a single institution (e.g. Wise et al., \91ia,b). In addition, the degree of
aminoglycoside-resistance was high in the strains tested in the present study. For
example, the gentamicin MIC's were ^4 and 5 8 mg/1 for 63% and 27% of isolates,
respectively; the corresponding figures for tobramycin resistance were 21% and 15%.
Amikacin MIC's were 5:8 mg/1 for 42% of isolates; the MICs were ^ 16 mg/1 for 19%.
Resistance to all three currently available aminoglycosides occurred in 13% of the Ps.
aeruginosa isolates overall. Our present experiments evaluated MIC values only against
this large number of isolates; MBCs were done only on the isolates selected for in-vivo
study. Some authors have argued that azlocillin (and other ureidopenicillins) are less
rapidly bactericidal than ticarcillin (White et al., 1980) while this has not been noted by
others (Coppens & Klastersky, 1979). The clinical relevance requires further
experimentation and study, but this type of difference in bactericidal activity may
influence the results in vivo in experimental animal models of infection (see below).
Azlocillin was less effective than cefsulodin in the experiments with Ps. aeruginosa
pyelonephritis in rats reported here (Table I). Several explanations are possible for this
finding. The MBC for the test strain was eight-fold higher for azlocillin than for
cefsulodin. In addition, the half-life of azlocillin in rat serum is extremely short,
approximately eight minutes (Figure 2; Scheld et al., unpubl. data) and therapeutic
serum levels were maintained with cefsulodin for much longer periods. Indeed, the rat
may prove unsuitable for the evaluation of ureidopenicillins in vivo.
Ticarcillin proved more effective in rendering kidneys free of infection than azlocillin
in the mouse model of experimental pyelonephritis (Table II; Beale et al., 1982). This
may relate to the enhanced bactericidal activity of ticarcillin noted by some
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investigators (White et al., 1980) but the reasons for the differences noted in vivo are
not known. The mouse pyelonephritis study does not include data on relative
MICs/MBCs, serum or tissue concentrations of antibiotics, the presence of renal
failure etc., which may be of critical importance to in-vivo efficacy. All of the drugs
evaluated were present in large concentrations in the urine of the experimental mice
(^350-1100 mg/1) and far exceeded the MIC of the Ps. aeruginosa strains evaluated.
Other factors, including renal concentration of drug, protein-binding in vivo,
leukocyte responses, or the generation of a 'post-antibiotic effect' were not pursued
and may explain partially differences in in-vivo efficacy in these two models of
experimental pyelonephritis. Despite excellent activity against Streptococcus faecalis in
vitro, azlocillin has not been evaluated in the well characterized model of rat
enterococcal pyelonephritis (Guze, Hubert & Kalmanson, 1963). Further animal
model experiments and clinical trials are necessary to determine if azlocillin (or other
new /Mactams) will be as active as the aminoglycosides (with reduced toxicity) in
pyelonephritis due to other pathogens (e.g. ampicillin or carbenicillin resistant
Enterobacteriaceae).
Azlocillin was disappointing in the experiments with chronic Ps. aeruginosa
osteomyelitis reported here (Table III). When administered alone for 28 days, azlocillin
did not reduce the incidence of positive bone cultures after death on day 70 when
compared to untreated controls. Similar results were noted with carbenicillin, however
(Norden & Keleti, 1980). The results were improved to a 60% positive bone culture
rate with combined azlocillin-tobramycin therapy, but this was not significantly better
than results obtained with tobramycin alone (Table HI). In addition, this result is
inferior to a 30% positive bone culture rate obtained with a carbenicillin-sisomicin
regimen in an earlier study (Norden & Keleti, 1980). The reasons for this discrepancy
are not entirely clear. The MIC for carbenicillin against the Ps. aeruginosa strain used
was 62-5 mg/1, vs. 12-5 mg/1 for azlocillin, when an inoculum of ^ 10s cfu was used in
the in-vitro conditions. A significant 'inoculum effect' was noted for azlocillin against
this test isolate when the inoculum was raised to 107 cfu in vitro; the MIC increased
from 12-5 to > 500 mg/1 whereas the change with carbenicillin was more modest (62-5
to 250 mg/1) (Norden & Shaffer, 1982). This is unlikely to explain the relative efficacy
of each drug because of the following factors: (1) bone concentrations rarely exceed
106 cfu in vivo in this model, concentrations where an inoculum effect is not
demonstrable in vitro; and (2) the concentrations relevant to the MIC determination at
an inoculum of 107 cfu (e.g. ^250 mg/1) are far above attainable bone concentrations
for either agent. Another possible explanation is the dosing interval used in these
experiments. The protocol used permits long intervals between drug dosages
(e.g. =: 12 h), even with combination regimens, and prolonged periods with suboptimal
serum levels resulted. However, identical intervals were used for both the
azlocillin-tobramycin and carbenicillin-sisomicin regimens. Finally, no attempt was
made for data analysis in regard to differences in the mean log,0 cfu Ps. aeruginosa per
bone flush obtained after death where 'positive' could indicate as few as 1-2 cfu/ml of
flush. The various treatment regimens may differ when this parameter is used in
analysis.
A large number of antibiotics have been evaluated in the well-characterized model of
experimental peritonitis and intraabdominal abscess in rats (Bartlett el al., 1981). The
model involves the intraperitoneaJ insertion of gelatin capsules containing caecal
contents from meat-fed rats mixed with prereduced peptone yeast glucose broth and
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barium sulphate, and is characterized by an early peritonitis stage caused by coliforms
with =^ 40% mortality followed by a later intra-abdominal abscess stage with Bacteroides
fragilis as the predominant isolate (Weinstein et al., 1974; Onderdonk et al., 1974,
1977). In general, antibiotics with anti-coliform activity reduced early mortality,
whereas drugs with activity against Bad. fragilis prevented late abscess formation
(Weinstein et al., 1975; Bartlett et al. 1978, 1981).
Although azlocillin has not been evaluated in this rat model of peritonitis—intra-
abdominal abscess, two closely related agents (mezlocillin, piperacillin) were studied
recently (Bartlett, Marien & Dezfulian, 1982) in a subcutaneous abscess model in mice
induced by the inoculation of 0-25 ml containing 25% autoclaved caecal contents plus
107 2 cfu Bad. fragilis strain ATCC 23745. When the drugs were begun five days after
therapy and continued at 600-800 mg/kg q8h for four doses, pharmacokinetic analysis
revealed mean peak abscess concentrations of 44-113 mg/1 (19-29% of mean peak
serum levels) for carbenicillin, mezlocillin and piperacillin. These results are
comparable to those achieved with other /Mactam agents, and reflect some modest in-
vivo hydrolysis by Bad. fragilis /?-lactamase (Bartlett et al., 1982). When treatment was
begun 1 h after challenge and continued every 8 h for five days, and the number of
Bad. fragilis/abscess determined at sacrifice, the mean ±S.E.M. decreases in log
 10 cfu
bacterial concentrations observed were as follows: mezlocillin =—0-4 + 0 1 ;
carbenicillin = —10 ±0-3; piperacillin = —2-6 ±0-6. These results must be compared
with those obtained with drugs employed commonly in Bad. fragilis infections, where
the mean + s.E.M. decreases in bacterial concentration (log10 cfu/abscess) were as
follows: metronidazole = — 6-7 + 0-6, clindamycin = — 50±0-6; cefoxitin
= —3-5 ±0-5; and chloramphenicol = —1-6 ±0-5. Thus, the ureidopenicillins were not
as effective as several older agents in this experimental model of Bad. fragilis abscess.
Ps. aeruginosa endocarditis remains a difficult form of this disease in prosthetic valve
recipients and intravenous drug abusers (Slaughter, Morris & Starr, 1973; Reyes et al.,
1973). Antimicrobial therapy, usually an aminoglycoside-/?-lactam combination, is
rarely curative in Ps. aeruginosa endocarditis involving the left-side of the heart, and
mortality rates often exceed 80%. An excellent model of experimental Ps. aeruginosa
endocarditis was developed by Archer & Fekety (1976, 1977); a modification of this
model was used in the experiments with azlocillin-containing regimens reported here.
Although both ticarcillin and azlocillin reduced vegetation Ps. aeruginosa titres
significantly (•- 005) when compared to untreated controls in this model (Table IV),
both agents were less effective than tobramycin alone. These results cannot be
correlated directly with the serum bactericidal activity measured in vivo with the
regimens. Tobramycin alone (at 5 mg/kg) was more effective than gentamicin alone
(at 5 or 7-5 mg/kg) in the earlier studies (Archer & Fekety, 1977) despite similar MBCs,
serum pharmacokinetics and bactericidal activity, even when gentamicin was given for
6 or 14 days as opposed to only five days of tobramycin in our experiments. The
tobramycin-ticarcillin regimen was not more effective than tobramycin alone in the
present study (Table IV). In contrast, a gentamicin-carbenicillin regimen (at higher
dosages) was more effective than either agent alone in the earlier study (Archer &
Fekety, 1977). These differences, however, were only apparent after a full 14 days of
therapy and were most noteworthy in prevention of relapses rather than reduction in
Ps. aeruginosa concentrations within vegetations. This data is consistent with our short
(5 day) treatment intervals, although the incidence of relapse was not evaluated in our
study. Although the azlocillin-tobramycin regimen produced the lowest Ps. aeruginosa
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concentrations within the vegetations, only 4 of 14 animals had sterile valves on
killing after five days. Similar results were obtained after six days of
gentamicin-carbenicillin therapy (Archer & Fekety, 1977) and only 64% (9/14) were
sterile after 14 days of treatment with this regimen. Thus, this model of experimental
Ps. aeruginosa endocarditis, like the human disease, is very recalcitrant to
antimicrobial therapy, and improved regimens are still needed.
Meningitis due to Gram-negative aerobic bacilli is increasing in frequency (Mangj,
Quintiliani & Andriole, 1975; Crane & Lerner, 1978; Cherubin et al., 1981) and
mortality rates remain distressingly high despite systemic, intrathecal, or
intraventricular aminoglycosides alone or in combination with other antimicrobials
(McCracken & Mize, 1976; McCracken, Mize & Threlkeld, 1980). Ps. aeruginosa is an
unusual aetiologic agent in these cases, accounting for a* 5% of bacterial meningitis in
neonates, and is associated with a high mortality rate (Wise, Mathis & Jawetz, 1969;
Johnston & Speller, 1977). Although therapy of Gram-negative bacillary meningitis
may improve with the use of new agents (e.g. moxalactam, cefotaxime),
aminoglycosides are still required when the disease is due to Ps. aeruginosa due to poor
activity of these new drugs against this agent at concentrations attainable in purulent
CSF in vivo. An experimental model was developed to study these problems in more
detail.
A large number of antimicrobials have been evaluated in experimental Ps.
aeruginosa meningitis with short (8 h) intravenous infusions (Table V; Scheld, Kelly &
Sande, 1980; Scheld et al., 1982). The percentage penetration ([CSF]/[serum] x 100) was
very reproducible and consistent for each agent (Table V); these values were usually
> 25% for the aminoglycosides, in close agreement with earlier studies (Strausbaugh &
Sande, 1978). The percentage penetration of mezlocillin and azlocillin were similar
^13-5%, and this value compares favourably with other /Mactam agents tested in
experimental meningitis (Dacey & Sande, 1974; Bodine, Strausbaugh & Sande, 1976;
Scheld et al., \919a,b, 1982; Scheld & Sande, 1982; Schaad et al., 1981; Perfect &
Durack, 1981; Hodges & Norley, 1982).
Despite mean CSF antibiotic concentrations that exceeded the MBC of the test
strain by several-fold, none of the single-agent regimens was particularly effective in
experimental Ps. aeruginosa meningitis (Table VI, Figure 4). The best results with
monotherapy were noted with azlocillin, piperacillin and cefsulodin where the ratio of
the CSF concentration to the MBC of the test strain was the highest. Despite this
activity, a sterile CSF was never achieved after the 8 h infusion period. The most rapid
bactericidal activity was achieved in vivo with combination therapy, especially
azlocillin-amikacin (Table VI). Similar results were obtained with a
cefsulodin-amikacin regimen and this, plus other combinations, require further
testing. When compared to other forms of experimental meningitis, the rate of decline
of Ps. aeruginosa concentration in CSF in this model is slow, despite adequate drug
levels in vivo. The reasons for this are not clear but may relate to the low pH of
purulent CSF (mean = 6-95 in this model) which inhibits aminoglycoside activity, and
the slow rate of Ps. aeruginosa growth in CSF (> 100 min vs. 20 min in broth; unpubl.
data) which may inhibit the response to cell-wall active agents in vivo. These areas
require further study. Azlocillin has been curative in Ps. aeruginosa meningitis in man
(Ellis & Walter, 1979), but carbenicillin has also been effective in selected cases
(Mombelli et al., 1982), when an aminoglycoside was also included. None of the new
(or old) /?-lactams should be used alone in Ps. aeruginosa meningitis, and the potential
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role for azlodllin in central nervous system infections requires more study.
Azlocillin is an active, new, anti-pseudomonal penicillin with proven efficacy in
selected human cases (Eliopoulos & Moellering, 1982; Eykyn, 1982; Levy, Baran &
Klastersky, 1982). In general, the experiments reported in vivo in the present paper
support and extend previous in-vitro observations. Nevertheless, multiple discrepancies
between in-vitro MIC/MBC data and in-vivo therapeutic efficacy in animals still exist,
and require further study. These models of experimental Ps. aeruginosa infections, like
the relevant human disease counterparts, are very resistant to cure with antibiotics,
even when given in combination for prolonged periods. Various azlocillin (or
piperacillin, cefsulodin)-aminoglycoside regimens appear most active in vivo and may
improve results in humans. It should be noted, however, that animal models may be
discriminative or predictive but still suffer from difficulties in interpretation (Brown,
1981); the ultimate significance of the experiments reported in the present study
require properly controlled prospective clinical trials.
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